Literature DB >> 8049646

Cellular characteristics of acute myeloblastic leukemia associated with t(8;21)(q22;q22). The Japanese Cooperative Group of Leukemia/Lymphoma.

K Kita1, S Shirakawa, N Kamada.   

Abstract

A large number of AML cases is reviewed in order to clarify biological characteristics of t(8;21) AML cells. The incidence of positivities for stem cell antigens, CD34 and HLA-DR, on blasts in t(8;21) AML is higher in comparison with those in other M2 or M3 categories. Frequent expression of CD34 and HLA-DR is indicative of the stem cell derivation of t(8;21) AML cells. The non-blastic leukemic cells in t(8;21) AML tend to lose the immature phenotype with discordant maturation such as low CD33 expression. Further, the blasts show frequent expression of the B-cell antigen, CD19, without other B-cell antigens and immunoglobulin gene rearrangements. AML cells with t(8;21) showed poorer response to granulocyte-macrophage colony-stimulating factor (GM-CSF) due to a decreased number of GM-CSF binding sites. The absence of monocytic differentiation in t(8;21) AML cells might represent the abnormal response to growth factors at the bifurcation stage of granulocyte and monocyte differentiation. Recently, breakpoint region genes for the 8;21 translocation in chromosome 8 and 21 have been isolated, 48-50 and have been named AML1 and ETO, respectively. The AML1 gene showed a strong homology with the Drosophila segmentation gene, runt, which is thought to be necessary for the Sex lethal gene expression. Since the GM-CSF receptor alpha chain gene locates in the pseudoautosomal region of the sex chromosome, the decrease of GM-CSF binding sites might be related to the AML1/ETO fusion gene expression. Further molecular genetic investigations of the breakpoint genes in the future are expected to clarify the unique biological events seen in this type of leukemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049646     DOI: 10.3109/10428199409056286

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.

Authors:  Shinobu Matsuura; Ming Yan; Miao-Chia Lo; Eun-Young Ahn; Stephanie Weng; David Dangoor; Mahan Matin; Tsunehito Higashi; Gen-Sheng Feng; Dong-Er Zhang
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

3.  RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1.

Authors:  K Liddiard; A K Burnett; R L Darley; A Tonks
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

4.  Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity.

Authors:  S Weng; S Matsuura; C T Mowery; S A Stoner; K Lam; D Ran; A G Davis; M-C Lo; D-E Zhang
Journal:  Leukemia       Date:  2016-06-15       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.